CHARLES M. BAUM - 28 Nov 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
President,Founder,Head of R&D, Director
Signature
/s/ Reena R. Desai, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Nov 2022
Net transactions value
-$5,719,853
Form type
4
Filing time
28 Nov 2022, 18:01:47 UTC
Previous filing
16 Jun 2022
Next filing
21 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Options Exercise $1,205,747 +69,256 +54% $17.41 197,155 28 Nov 2022 Direct F1
transaction MRTX Common Stock Sale $6,925,600 -69,256 -35% $100.00 127,899 28 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Employee Stock Option (Right to Buy) Options Exercise $0 -69,256 -50% $0.000000 69,258 28 Nov 2022 Common Stock 69,256 $17.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.